Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01116271 · ClinicalTrials.gov registry record · Phase 2
Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec
A Phase 2 study of Colorectal Cancer, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 12
- Study locations
NCT01116271: Completed Phase 2 study of Colorectal Cancer, sponsored by AstraZeneca.
NCT01116271 is a Phase 2 study of Colorectal Cancer that has completed, run by AstraZeneca. The registered enrollment target is 32 participants, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (98% lower). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01116271, a Phase 2 study of Colorectal Cancer, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to determine whether treatment with Selumetinib (AZD6244) (Hyd-Sulfate) in combination with Irinotecan as a second treatment in patients with K-ras or B-raf mutation will prevent tumor progression and prolong progression free survival.
Conditions Studied
Interventions
- DRUG Irinotecan
- DRUG AZD6244
Study Locations (12)
North Carolina
- Reserach Site - Chapel Hill
- Research Site - Greenville
- Research Site - Washington
California
- Research Site - Los Angeles
- Research Site - Palm Springs
Colorado
- Research Site - Aurora
Connecticut
- Research Site - New Haven
Delaware
- Research Site - Newark
Florida
- Research Site - Miami Beach
New York
- Research Site - New York
Pennsylvania
- Research Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
What the finished NCT01116271 record still lists
NCT01116271 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Irinotecan is the first listed.
NCT01116271 lists 12 locations in 9 states (North Carolina, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT01116271 about?
NCT01116271 is a clinical study titled "Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec". The purpose of this study is to determine whether treatment with Selumetinib (AZD6244) (Hyd-Sulfate) in combination with Irinotecan as a second treatment in patients with K-ras or B-raf mutation will prevent tumor progression and prolong progression free survival.
What is the current status of trial NCT01116271?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2010-04. Estimated completion is 2012-07.
What conditions does trial NCT01116271 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT01116271?
The interventions under investigation include: Irinotecan (DRUG), AZD6244 (DRUG).
Who is sponsoring clinical trial NCT01116271?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01116271 being conducted?
This trial has 12 study locations across California, Colorado, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01116271's enrollment target sits among peer trials
32 318th of 381 higher than 60 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia